Novavax near historic lows caused by weak outllook and financial challenges 📉

23:41 2 āļĄāļĩāļ™āļēāļ„āļĄ 2023

Novavax (NVAX.US), the maker of Nuvaxovid, an anti-covid-19 drug, had been experiencing strong revenues over the past few years, but these ended with the passing of the pandemic and were replaced by financial challenges.  The company has not vavax kept up with its anti-covid product with 'faster competition' which has dominated the market faster with mRNA vaccines. Yesterday, Novavax warned that it may not survive in the current environment, prompting a panicked reaction from investors.

Shares of Moderna (MRNA.US), Pfizer (PFE.US) and Biontech (BNTX.US) have also fallen in recent bottoms as Wall Street begins to worry that results from the pandemic will become impossible to repeat in the coming years.

āđ€āļĢāļīāđˆāļĄāđ€āļ—āļĢāļ”āļ—āļąāļ™āļ—āļĩāļ§āļąāļ™āļ™āļĩāđ‰ āļŦāļĢāļ·āļ­ āļĨāļ­āļ‡āđƒāļŠāđ‰āļšāļąāļāļŠāļĩāļ—āļ”āļĨāļ­āļ‡āđāļšāļšāđ„āļĢāđ‰āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡

āđ€āļ›āļīāļ”āļšāļąāļāļŠāļĩ āļĨāļ­āļ‡āļšāļąāļāļŠāļĩāđ€āļ”āđ‚āļĄāđˆ āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļ­āļ›āļĄāļ·āļ­āļ–āļ·āļ­ āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļ­āļ›āļĄāļ·āļ­āļ–āļ·āļ­
  • Novavax indicates that future sales as well as funding for the business from the US government remain highly uncertain;
  • The company has nearly $1.3 billion in cash but spent $182 million in the fourth quarter and $658 million through 2022;
  • Despite the weaker outlook, CEO John Jacobs that, based on its existing foundation, the company has potential for the future although it faces big challenges
  • The company needs to deliver a competitive product for the 2023 vaccination season, reduce the rate at which it burns cash, better manage cash flow and most importantly - expand its offer and sales beyond just Nuvaxovid which, however, will require money and time.

Novavax (NVAX.US) shares, W1 interval. Source: xStation5

āļŦāļļāđ‰āļ™:
āļāļĨāļąāļšāđ„āļ›

āļ‚āđˆāļēāļ§āđƒāļ™āļ•āļĨāļēāļ”āļāļēāļĢāđ€āļ‡āļīāļ™

27.08.2025
09:36

☕ āļāļēāđāļŸāļĢāđˆāļ§āļ‡āđ€āļāļ·āļ­āļš 3% 📉 āļŦāļĨāļąāļ‡ StoneX āļ„āļēāļ”āļāļēāļĢāļ“āđŒāļœāļĨāļœāļĨāļīāļ•āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™āđƒāļ™āļĪāļ”āļđāļāļēāļĨ 2026/27

āļŠāļąāļāļāļēāļĨāđˆāļ§āļ‡āļŦāļ™āđ‰āļē Arabica āļšāļ™ ICE (COFFEE) āļĢāđˆāļ§āļ‡āļ§āļąāļ™āļ™āļĩāđ‰ āļˆāļēāļāđāļĢāļ‡āļ‚āļēāļĒāļ—āļģāļāļģāđ„āļĢāđāļĨāļ°āļāļēāļĢāļ›āļīāļ”āļŠāļ–āļēāļ™āļ° Long āđāļĄāđ‰āļ§āđˆāļē StoneX āļˆāļ°āļ›āļĢāļąāļšāļĨāļ”āļ„āļēāļ”āļāļēāļĢāļ“āđŒāļœāļĨāļœāļĨāļīāļ•āļāļēāđāļŸāļšāļĢāļēāļ‹āļīāļĨ āļĪāļ”āļđāļāļēāļĨ 2025/26...

09:34

āđ‚āļāđ‚āļāđ‰āļĢāđˆāļ§āļ‡āļĨāļ‡ 4% 📉

āļŠāļąāļāļāļēāļĨāđˆāļ§āļ‡āļŦāļ™āđ‰āļēāđ‚āļāđ‚āļāđ‰āđāļ•āļ°āļĢāļ°āļ”āļąāļšāļŠāļđāļ‡āļŠāļļāļ”āđƒāļ™āļĢāļ­āļšāļŠāļ­āļ‡āđ€āļ”āļ·āļ­āļ™ āđ„āļ”āđ‰āđāļĢāļ‡āļŦāļ™āļļāļ™āļˆāļēāļāļ„āļ§āļēāļĄāļāļąāļ‡āļ§āļĨāļ”āđ‰āļēāļ™āļ­āļļāļ›āļ—āļēāļ™ āļ—āđˆāļēāļĄāļāļĨāļēāļ‡āļŠāļ āļēāļžāļ­āļēāļāļēāļĻāđāļŦāđ‰āļ‡āđāļĨāļ°āđ€āļĒāđ‡āļ™āđƒāļ™āđāļ­āļŸāļĢāļīāļāļēāļ•āļ°āļ§āļąāļ™āļ­āļ­āļ āļ­āļĒāđˆāļēāļ‡āđ„āļĢāļāđ‡āļ•āļēāļĄ āļĢāļēāļ„āļēāļāļĨāļąāļšāļ›āļĢāļąāļšāļāļēāļ™āļĨāļ‡...

26.08.2025
17:59

DE40: āļ„āļ§āļēāļĄāļ§āļļāđˆāļ™āļ§āļēāļĒāļ—āļēāļ‡āļāļēāļĢāđ€āļĄāļ·āļ­āļ‡āđƒāļ™āļāļĢāļąāđˆāļ‡āđ€āļĻāļŠāļāļ”āļ”āļąāļ™āļ”āļąāļŠāļ™āļĩāļĒāļļāđ‚āļĢāļ›

āļĄāļĩāļ„āļ§āļēāļĄāļĢāļđāđ‰āļŠāļķāļāļāļąāļ‡āļ§āļĨāļŠāļąāļ”āđ€āļˆāļ™āđƒāļ™āļ•āļĨāļēāļ”āļāļēāļĢāđ€āļ‡āļīāļ™āļĒāļļāđ‚āļĢāļ›āđƒāļ™āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ™āļĩāđ‰ āļ™āļąāļāļĨāļ‡āļ—āļļāļ™āļˆāļąāļšāļ•āļēāļĄāļ­āļ‡āļŦāļļāđ‰āļ™āļāļĢāļąāđˆāļ‡āđ€āļĻāļŠāļ­āļĒāđˆāļēāļ‡āđƒāļāļĨāđ‰āļŠāļīāļ” āļ‹āļķāđˆāļ‡āļ­āļēāļˆāđ€āļœāļŠāļīāļāļāļąāļšāļ„āļ§āļēāļĄāļœāļąāļ™āļœāļ§āļ™āļŠāļđāļ‡āļ­āļĩāļāļ„āļĢāļąāđ‰āļ‡ āļŸāļīāļ§āđ€āļˆāļ­āļĢāđŒāļŠāļ‚āļ­āļ‡āļ”āļąāļŠāļ™āļĩ...

āđ€āļ‚āđ‰āļēāļŠāļđāđˆāļ•āļĨāļēāļ”āļžāļĢāđ‰āļ­āļĄāļĨāļđāļāļ„āđ‰āļēāļ‚āļ­āļ‡ XTB Group āļāļ§āđˆāļē 1 700 000 āļĢāļēāļĒ

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ